Pages that link to "Q40442632"
Jump to navigation
Jump to search
The following pages link to The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review (Q40442632):
Displaying 50 items.
- High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller (Q24641848) (← links)
- Young age: an independent risk factor for disease-free survival in women with operable breast cancer (Q24791855) (← links)
- C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer (Q24795406) (← links)
- HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies (Q26822730) (← links)
- The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in vivo (Q26827175) (← links)
- Predictive diagnosis of the risk of breast cancer recurrence after surgery by single-particle quantum dot imaging (Q30665854) (← links)
- Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. (Q30857631) (← links)
- Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells (Q31055338) (← links)
- The role of trastuzumab in early stage breast cancer: current data and treatment recommendations (Q31120100) (← links)
- Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study (Q33415078) (← links)
- Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients (Q33415375) (← links)
- c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients (Q33538427) (← links)
- A novel role for 14-3-3sigma in regulating epithelial cell polarity (Q33816790) (← links)
- Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? (Q33820233) (← links)
- ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression (Q33829405) (← links)
- Signal transduction in mammary tumorigenesis: a transgenic perspective (Q33860827) (← links)
- ErbB2 activation and signal transduction in normal and malignant mammary cells (Q33962777) (← links)
- Ductal carcinoma in situ. Implications for screening mammography (Q34003496) (← links)
- Pathogenesis, prevention, diagnosis and treatment of breast cancer (Q34023647) (← links)
- miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer. (Q34048535) (← links)
- Prognostic and Predictive Factors for Breast Cancer (Q34089296) (← links)
- Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study (Q34129444) (← links)
- Transgenic mouse models of human breast cancer (Q34130558) (← links)
- Oncogenes and tumor suppressor genes (Q34149922) (← links)
- Overexpression of the amplified Pip4k2beta gene from 17q11-12 in breast cancer cells confers proliferation advantage (Q34285811) (← links)
- Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients (Q34344146) (← links)
- The significance of immunohistochemistry in the diagnosis and therapy of neoplasms (Q34602545) (← links)
- Breast cancer arising within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policy (Q34897785) (← links)
- Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer (Q35035776) (← links)
- Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future? (Q35157568) (← links)
- Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast Carcinoma (Q35504371) (← links)
- The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer (Q35555254) (← links)
- Emerging drugs for non-small cell lung cancer (Q35581167) (← links)
- YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention (Q35640233) (← links)
- Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer (Q35773929) (← links)
- Analysis of molecular aberrations in ovarian cancer allows novel target identification (Q35777532) (← links)
- Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer (Q35809752) (← links)
- Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma (Q35855473) (← links)
- T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors (Q35949083) (← links)
- Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient (Q36062188) (← links)
- Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence (Q36115781) (← links)
- Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections (Q36135626) (← links)
- Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer (Q36293034) (← links)
- Her2 positivity and race predict higher mastectomy rates: a SEER database analysis (Q36308052) (← links)
- Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2-positive breast cancer in Japan (Q36336483) (← links)
- c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival (Q36421775) (← links)
- Immunohistochemical categorisation of ductal carcinoma in situ of the breast (Q36608698) (← links)
- Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. (Q36611699) (← links)
- Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer (Q36673717) (← links)
- Microcalcification-Associated Breast Cancer: Presentation, Successful First Excision, Long-Term Recurrence and Survival Rate (Q36682390) (← links)